Double-Digit Gains Ahead? These 2 Cybersecurity Stocks Look Ready — Positive
FTNT NET MarketBeat — February 13, 2025Fortinet NASDAQ: FTNT and Cloudflare NYSE: NET are two cybersecurity stocks poised for double-digit gains in 2025. They are poised for double-digit gains because of their differentiated positions in a rapidly growing market, utility to clients, 2024 results, 2025 guidance, cash flow, and analysts' sentiment.

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial — Positive
LLY MarketBeat — February 13, 2025Eli Lilly and Company NYSE: LLY is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close.

DraftKings Stock Ready For Another Post-Earnings Pop — Positive
DKNG Schaeffers Research — February 13, 2025You'd have to look far and wide to find an area of Wall Street not rattled by tariffs or Trump trade.

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease — Neutral
EVGN PRNewsWire — February 13, 2025Initial fungicidally active compounds already discovered REHOVOT, Israel , Feb. 13, 2025 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd.

Foremost Clean Energy to Attend Prospectors & Developers Association of Canada (PDAC) 2025 Convention — Neutral
FMST GlobeNewsWire — February 13, 2025VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”), a rapidly growing North American American uranium and lithium exploration company is pleased to announce that it is participating for the first two days in the upcoming Prospectors & Developers Association of Canada (PDAC) 2024 Convention – the world's premier mineral exploration & mining convention – taking place March 02-05, 2025 at the Metro Toronto Convention Centre (MTCC) in Toronto, Canada.

Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update — Neutral
AMIX GlobeNewsWire — February 13, 2025Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer with topline data on track for 1H 2025

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model — Neutral
CDT GlobeNewsWire — February 13, 2025Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes. The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN).

New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care — Neutral
DXR GlobeNewsWire — February 13, 2025Research Published in the Prestigious Journal of Cardiac Failure From Three Institutions Oak Ridge, TN, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor's Blood Volume Analysis (BVA). The study demonstrates how BVA outperforms standard hemodynamic measurements in assessing heart failure volume status, while highlighting its unique capability to detect anemia, a crucial factor for effective treatment.

red violet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 — Neutral
RDVT GlobeNewsWire — February 13, 2025BOCA RATON, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024 after the close of the U.S. financial markets on Thursday, February 27, 2025.

Nucor: Time To Build A Position For The Next Cycle In The Megatrend (Rating Upgrade) — Positive
NUE Seeking Alpha — February 13, 2025I am upgrading NUE shares to a BUY rating with a price target of $152/share, driven by supportive tariffs and strong market outlooks across key industries. Nucor may not be significantly impacted by tariffs as most of its steel exports are high-value-added products as opposed to commoditized steel. Nucor's long-term growth may be supported by multiple megatrends, including nearshoring, data center construction, and power transmission.

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update — Neutral
SONN GlobeNewsWire — February 13, 2025Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR)

Locafy Introduces Localizer, a Powerful Solution to Boost Local Search Visibility and Drive Partner-Led Growth — Neutral
LCFY GlobeNewsWire — February 13, 2025Recurring revenue growth from partners exceeds $35,000 per month after a few weeks $25,000 in monthly cost reductions anticipated after converting salaried sales staff to Partners program Scalable-location based digital marketing solution appeals to multi-location businesses PERTH, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized leader in location based digital marketing solutions, with market leading SEO capabilities, today announced the launch of Localizer, a powerful solution designed to help businesses improve their online visibility and rank higher in local search results. With 46% of Google searches seeking local products …

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis — Neutral
PLRX GlobeNewsWire — February 13, 2025SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial's independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).

Reply Announces the Launch of Comwrap Reply to Expand Adobe Expertise in North America — Neutral
ADBE PRNewsWire — February 13, 2025ATLANTA , Feb. 13, 2025 /PRNewswire/ -- Reply, a global systems integrator and technology firm, is proud to announce the launch of Comwrap Reply in North America. This strategic expansion builds on Comwrap Reply's inception in 2004 and established presence in Germany, Italy, and the UK, enhancing its position as a leading provider of AI-powered, end-to-end digital experience solutions.

GDEV Aligns Leadership as Founder and CEO Andrey Fadeev Appointed Chairperson of the Board — Neutral
GDEV GlobeNewsWire — February 13, 2025GDEV Inc. announces the appointment of Andrey Fadeev, GDEV's founder and CEO and a member of the Company's Board of Directors, as Chairperson of the Board.

SUSSEX, Wis. , Feb. 13, 2025 /PRNewswire/ -- Quad/Graphics, Inc. (NYSE: QUAD) ("Quad" or the "Company"), a global marketing experience company, announced today that its Board of Directors approved an increase in the quarterly dividend on the Company's common stock from $0.05 per share, or $0.20 per share on an annualized basis, to $0.075 per share, or $0.30 per share on an annualized basis.

LiveOne (Nasdaq: LVO) Reports Record 9-Month Revenues of $95.1M — Neutral
LVO PODC GlobeNewsWire — February 13, 2025Financial Highlights Audio Division Record Revenue: $90.6M, +13% YoY; Q3 Fiscal 2025 Revenue: $27.1M Audio Division YTD Adjusted EBITDA*: $14.1M; Q3 Fiscal 2025: $3.6M Additional $44M in Contracted Revenue and B2B Deals Closed 5 B2B Deals, Expects to Close 2+ by Year-End, with 70+ in Pipeline 800K Tesla Subscribers, Including 475K+ Ad-Supported, Added 100k+ Following Presentation at Trump's Mar-a-Lago Cash: $10.9M as of Dec. 31, 2024 Cost Savings via Restructurings: $11M $12M Buyback Program Reaffirmed, with $6.2M Remaining PodcastOne (Nasdaq: PODC) LVO Owns ~72% of PodcastOne (Nasdaq: PODC) Acquired 342,000 PODC Shares this Quarter, Totaling 925,000 PODC Shares to Date …

Stryker to participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day — Neutral
SYK GlobeNewsWire — February 13, 2025Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York.

ZenaTech's ZenaDrone Subsidiary Develops and Tests Proprietary Drone Communications System Enabling Secure and Reliable Communications for US Defense Applications — Neutral
ZENA GlobeNewsWire — February 13, 2025VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces that its subsidiary ZenaDrone has developed and is currently testing a proprietary drone communications management system called “DroneNet” that enables direct and secure drone communications in situations without reliable internet, cellular or satellite communications. The internally developed system is specifically built for use with the Company's ZenaDrone 1000 and IQ series of drone products.

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 — Neutral
COLL GlobeNewsWire — February 13, 2025STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
